A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 27, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

July 31, 2026

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

IPI-145

oral PI3K delta/gamma inhibitor

DRUG

Fludarabine

intravenous chemotherapy

DRUG

Cyclophosphamide

intravenous chemotherapy

DRUG

Rituximab

intravenous immunotherapy

Trial Locations (2)

Beth Isreal Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Secura Bio, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02158091 - A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | Biotech Hunter | Biotech Hunter